Results 121 to 130 of about 5,090 (179)

False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T-VEC). [PDF]

J Surg Oncol, 2021
Mulder EEAP, Stahlie EHA, Verver D, Lemstra C, Been LB, Mooyaart AL, Brabander T, Vegt E, Verburg FA, van der Veldt AAM, Verhoef C, van Akkooi ACJ, Grünhagen DJ.   +12 more
europepmc   +1 more source

Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer. [PDF]

Oncologist
Runcie K, Bracero Y, Samouha A, Manji G, Remotti HE, Gonda TA, Saenger Y.   +6 more
europepmc   +1 more source

Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma. [PDF]

Melanoma Res, 2022
Mulder EEAP, Damman J, Verver D, van der Veldt AAM, Tas S, Khemai-Mehraban T, Heezen KC, Wouters RA, Verhoef C, Verjans GMGM, Langerak AW, Grünhagen DJ, Mooyaart AL.   +12 more
europepmc   +1 more source

Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review. [PDF]

Curr Oncol Rep
Kalsi S, Galenkamp AL, Singh R, Khosla AA, McGranaghan P, Cintolo-Gonzalez J.   +5 more
europepmc   +1 more source

A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. [PDF]

Sci Rep, 2021
Kai M, Marx AN, Liu DD, Shen Y, Gao H, Reuben JM, Whitman G, Krishnamurthy S, Ross MI, Litton JK, Lim B, Ibrahim N, Kogawa T, Ueno NT.   +13 more
europepmc   +1 more source

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells. [PDF]

Front Immunol, 2021
Tijtgat J, De Munck J, Dufait I, Schwarze JK, Van Riet I, Franceschini L, Breckpot K, Aerts JL, Neyns B, Tuyaerts S.   +9 more
europepmc   +1 more source

Talimogene Laherparepvec Regimen [PDF]

, 2020
openaire   +1 more source

Combined Regional Approach of Talimogene laherparepvec and Radiotherapy in the Treatment of Advanced Melanoma. [PDF]

Cancers (Basel)
Tam A, Ladbury C, Kassardjian A, Modi B, McGee H, Melstrom L, Margolin K, Xing Y, Amini A.   +8 more
europepmc   +1 more source

Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial). [PDF]

Nat Cancer
Ressler JM, Plaschka M, Silmbrod R, Bachmayr V, Shaw LE, Silly T, Zila N, Stepan A, Kusienicka A, Tschandl P, Tittes J, Roka F, Haslik W, Petzelbauer P, Koenig F, Kunstfeld R, Farlik M, Halbritter F, Weninger W, Hoeller C.   +19 more
europepmc   +1 more source

A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors. [PDF]

Radiother Oncol
Barker CA, D'Angelo SP, Wasilewski G, Steckler AM, Lian M, Zhang Z, Chapman PB, Shoushtari AN, Ariyan CE.   +8 more
europepmc   +1 more source